Mark J.  Alles net worth and biography

Mark Alles Biography and Net Worth

Mark J. Alles joined our Board in January 2022 and serves as Chair of the CGN Committee. Mark J. Alles served as CEO of Celgene Corporation, a global biopharmaceutical company, from March 2016 to January 2018, and as Chairman and CEO from February 2018 until its acquisition by Bristol Myers Squibb Company in November 2019. Prior to these roles, Mr. Alles served as Celgene’s President and Chief Operating Officer from August 2014 to February 2016 and as its Chief Commercial Officer and Executive Vice President, Hematology & Oncology from December 2012 to July 2014. Mr. Alles first joined Celgene in 2004 and served in a number of commercial management positions of increasing responsibility at the company. Before joining Celgene, Mr. Alles held senior commercial management roles at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) from 1993 to 2004. Mr. Alles was Chairman of Turning Point Therapeutics, Inc., a public oncology company acquired by Bristol Myers Squibb in 2022, serves on the boards of Antengene Corporation Limited and Syros Pharmaceuticals, Inc., both public biopharmaceutical companies, and is Executive Chairman of TORL BioTherapeutics, LLC and PIKSci, Inc., both private biotechnology companies. Mr. Alles received a bachelor’s degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps.

What is Mark J. Alles' net worth?

The estimated net worth of Mark J. Alles is at least $682,216.80 as of October 31st, 2022. Alles owns 10,905 shares of BioMarin Pharmaceutical stock worth more than $682,217 as of November 21st. This net worth evaluation does not reflect any other investments that Alles may own. Learn More about Mark J. Alles' net worth.

How do I contact Mark J. Alles?

The corporate mailing address for Alles and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on Mark J. Alles' contact information.

Has Mark J. Alles been buying or selling shares of BioMarin Pharmaceutical?

Mark J. Alles has not been actively trading shares of BioMarin Pharmaceutical during the past quarter. Most recently, on Monday, October 31st, Mark J. Alles bought 3,625 shares of BioMarin Pharmaceutical stock. The stock was acquired at an average cost of $86.75 per share, with a total value of $314,468.75. Following the completion of the transaction, the director now directly owns 10,905 shares of the company's stock, valued at $946,008.75. Learn More on Mark J. Alles' trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 209,971 shares worth more than $17,856,129.12. The most recent insider tranaction occured on November, 12th when EVP Charles Greg Guyer sold 5,278 shares worth more than $350,300.86. Insiders at BioMarin Pharmaceutical own 1.9% of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 11/12/2024.

Mark J. Alles Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/31/2022Buy3,625$86.75$314,468.7510,905View SEC Filing Icon  
See Full Table

Mark J. Alles Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Mark J Alles's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $62.56
Low: $61.61
High: $62.70

50 Day Range

MA: $69.08
Low: $61.93
High: $84.90

2 Week Range

Now: $62.56
Low: $61.15
High: $99.56

Volume

1,245,536 shs

Average Volume

1,829,197 shs

Market Capitalization

$11.92 billion

P/E Ratio

37.46

Dividend Yield

N/A

Beta

0.31